Financial Contrast: Acorda Therapeutics (ACOR) versus ProQR Therapeutics (PRQR)

Acorda Therapeutics (NASDAQ: ACOR) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Volatility and Risk

Acorda Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Insider & Institutional Ownership

31.6% of ProQR Therapeutics shares are held by institutional investors. 7.9% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Acorda Therapeutics and ProQR Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acorda Therapeutics 2 10 2 0 2.00
ProQR Therapeutics 0 1 3 0 2.75

Acorda Therapeutics presently has a consensus price target of $20.77, indicating a potential downside of 11.81%. ProQR Therapeutics has a consensus price target of $24.00, indicating a potential upside of 620.72%. Given ProQR Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Acorda Therapeutics.

Valuation & Earnings

This table compares Acorda Therapeutics and ProQR Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics $519.60 million 2.12 -$34.61 million ($1.21) -19.46
ProQR Therapeutics N/A N/A -$43.27 million ($2.06) -1.62

Acorda Therapeutics has higher revenue and earnings than ProQR Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Acorda Therapeutics and ProQR Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics -10.25% -8.18% -4.15%
ProQR Therapeutics N/A -97.68% -75.50%


Acorda Therapeutics beats ProQR Therapeutics on 7 of the 13 factors compared between the two stocks.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply